GSK Just Paid $10.6 Billion for This Precision Oncology Bet — Here’s What It Signals
The Nuvalent acquisition is the biggest biopharma deal of the week — and it’s rewriting the playbook for lung cancer investing.
Oracle beat. Then dropped 10%. Here is what nobody is talking about.
June 11, 2026 Oracle Beat Earnings and Still Got Punished The numbers were good. The reaction was worse. Here is…
Marvell Just Got Called the Next Trillion-Dollar Company. Here’s What the Numbers Actually Say.
MRVL posted record revenue and a wave of analyst upgrades. The question is whether the tape has already priced the future.
Goldman Sachs Just Repriced. The Question Is Whether It Deserves To Stay There.
Record equities, a four-year-high M&A backlog, and a SpaceX IPO mandate — GS is firing on almost every cylinder. Almost.
QCOM just got sold off with the wrong crowd
June 10, 2026 QCOM Got Lumped In. That Might Be the Opportunity. Edge-AI chips, a June 24 catalyst, and a…
The Healthcare Sector Has Been Left for Dead. That’s the Setup Bargain Hunters Have Been Waiting For.
Three years of underperformance, a 20% valuation discount, and a mean-reversion case that’s getting harder to ignore.
Broadcom Just Priced In Perfection. Then Delivered Something Slightly Less.
AVGO drops 12%+ on a quarter that beat EPS — here’s the real story behind the selloff
Stitch Fix reports tonight and the number that matters is not revenue
June 9, 2026 SFIX Reports Tonight Two signals. One winner. Q3 FY2026 drops after the bell. Two numbers have been…
CrowdStrike Just Split Its Stock. Here’s What the Valuation Debate Is Really About.
The cybersecurity leader crossed $5 billion in ARR and announced a 4-for-1 stock split. The post-earnings selloff may be the setup.
MercadoLibre Is Down 33% From Its Peak. That Might Be the Whole Story.
MELI posted 49% revenue growth in Q1 2026. The stock barely moved. Something doesn’t add up.